Osteosarcoma Pipeline Insight
DelveInsight’s, “Osteosarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Osteosarcoma, also called osteogenic sarcoma, is a kind of bone cancer. Most tumors develop in the bones around the knee, either in the lower part of the thigh bone (distal femur) or the upper part of the shinbone (proximal tibia). Osteosarcoma is the most common type of bone cancer, and accounts for about 3% of cancers that happen in children. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. The upper arm bone close to the shoulder (proximal humerus) is the next most common site. Osteosarcoma tumors can be categorized as low-grade, intermediate-grade, or high-grade. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Diagnosis of osteosarcoma is based on medical history and physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy.
"Osteosarcoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Osteosarcoma.
Osteosarcoma Emerging Drugs Chapters
This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteosarcoma Emerging Drugs
Pamufetinib: Taiho Pharmaceutical
Pamufetinib (formerly TAS 115) is an orally administered, ATP-competitive, small molecule based dual MET/VEGFR2 (KDR) receptor tyrosine kinase inhibitor. The drug is in Phase III clinical studies for the treatment of osteosarcoma and in Phase II clinical studies to treat idiopathic pulmonary fibrosis and prostate cancer.
Nivatrotamab: Y-mAbs Therapeutics
Nivatrotamab is a fully humanised bispecific antibody targeting both GD 2 and CD 3 receptors. The drug is in Phase II clinical studies for the treatment of neuroblastoma, osteosarcoma, and solid tumors.
Further product details are provided in the report……..
Osteosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Osteosarcoma
There are approx. 38+ key companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. Phase III include, Taiho Pharmaceutical.
DelveInsight’s report covers around 38+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Osteosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.
Osteosarcoma Report Insights
- Osteosarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Osteosarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Osteosarcoma drugs?
- How many Osteosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteosarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Osteosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?